Dry Eye Disease (DED)

What is Dry Eye Disease?

Dry eye disease, also known as keratoconjunctivitis sicca, is a multifarious disorder of the tears and the eye’s surface.2 The disease most commonly manifests in individuals aged 50 years or older and has a greater prevalence among women. Dry eye disease pathogenesis is not fully understood but is associated with risk factors of advanced age, female sex, wearing contact lenses, deficiency in vitamin A or omega-3 fatty acid consumption, autoimmune conditions, hormonal imbalances, irregular corneal innervation, environmental stress or infection, medication usage, and ophthalmic surgery.1, 2 Dry eye disease decreases an individual’s overall quality of life and can impede the performance of daily activities.2

 
A brown eye is shown with redness.

Signs and Symptoms 1

A perspective in public transport, where the left side of the image is blurred.

  • Scratchy eyes, the sensation of a foreign object in the eye

  • Burning feelings within the eye

  • Red eyes

  • Sensitivity to light

  • Blurred vision

 

Treatment for Dry Eye Disease

Currently, there is no cure or approved treatment that properly manages dry eye disease. There are only treatments that control some of the symptoms of the disease.1 The number of people affected in the United States is currently about 16 million Americans.1 Estimates in Europe are around and approximately 55 million individuals in Europe.

With this in mind, research and development for therapies are central to combating this disease.

 
The reVision icon logo, where the lower case letters of R and E are in a circle that from left to right transitions from dark blue to light blue.

reVision Therapeutics Seeks to Treat Dry Eye Disease

At reVision Therapeutics, our primary focus is to bring ophthalmic medicines rapidly to patients with unmet or poorly met disorders. 

Our dry eye disease candidate qualifies for short regulatory exclusivity in the United States and we are committed to using a molecule with significant disease impact.

Learn more about reVision’s program in dry eye disease.

 

Additional Dry Eye Disease Resources

To learn more about dry eye disease, below are additional materials and organizations that provide resources and support:

Disclaimer: These links are provided for your convenience. reVision Therapeutics, Inc. does not endorse the content of external websites. The content of these websites is not under the control, responsibility, or liability of reVision Therapeutics, Inc.

References

 

  1. Dry Eye | National Eye Institute. 22 Dec. 2020, https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/dry-eye#section-id-5932.

  2. Stevenson, William et al. “Dry eye disease: an immune-mediated ocular surface disorder.” Archives of ophthalmology (Chicago, Ill. : 1960) vol. 130,1 (2012): 90-100. doi:10.1001/archophthalmol.2011.364